03.08.2022 13:47:38
|
Moderna Q2 Results Top Estimates
(RTTNews) - Biotechnology company Moderna, Inc. (MRNA) reported a profit for the second quarter that increased from last year, reflecting improved revenues on commercial sales of the company's COVID-19 vaccine in the U.S.
Both earnings per share and revenues for the quarter topped analysts' expectations. The company also sees product sales for the fourth quarter to be higher than the third quarter.
For the second quarter, the company reported net income of $2.20 billion or $5.24 per share, down from $2.78 billion or $6.46 per share in the prior-year quarter.
On average, 13 analysts polled by Thomson Reuters expected the company to report earnings of $4.55 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter grew to $4.75 billion from last year's $4.35 billion, resulting from commercial sales of the company's COVID-19 vaccine. Analysts expected revenues of $4.07 billion for the quarter.
Product sales for the quarter increased 8 percent to $4.5 billion from last year, primarily driven by a higher average selling price due to customer mix.
Based on its strong financial position and commercial momentum, the Board of Directors has authorized an additional share repurchase program of $3 billion in August 2022 to return excess capital to shareholders.
Looking ahead to fiscal 2022, the company has already signed advance purchase agreements or APAs for product sales of approximately $21 billion for deliveries in 2022. This includes the recently announced agreement with the U.S. government for 70 million doses and an adjustment for doses that remain unallocated by COVAX due to lack of demand.
Moderna anticipates that for sales in the second half, sales will be greater in the fourth quarter than the third quarter, driven by the timing for approval of its updated COVID-19 vaccines.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Moderna Incmehr Nachrichten
08.01.25 |
S&P 500-Handel aktuell: S&P 500 bewegt sich zum Handelsende im Plus (finanzen.at) | |
08.01.25 |
Verluste in New York: Das macht der S&P 500 aktuell (finanzen.at) | |
08.01.25 |
Aufschläge in New York: Anleger lassen S&P 500 am Mittwochmittag steigen (finanzen.at) | |
08.01.25 |
Zurückhaltung in New York: S&P 500 präsentiert sich zum Start schwächer (finanzen.at) | |
07.01.25 |
NYSE-Handel S&P 500 beendet die Dienstagssitzung in der Verlustzone (finanzen.at) | |
07.01.25 |
Schwache Performance in New York: S&P 500 gibt nach (finanzen.at) | |
07.01.25 |
Minuszeichen in New York: Das macht der S&P 500 aktuell (finanzen.at) | |
07.01.25 |
Gewinne in New York: S&P 500 zum Handelsstart mit Gewinnen (finanzen.at) |
Analysen zu Moderna Incmehr Analysen
19.11.24 | Moderna Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
13.09.24 | Moderna Underweight | JP Morgan Chase & Co. | |
05.08.24 | Moderna Sector Perform | RBC Capital Markets | |
12.01.24 | Moderna Outperform | RBC Capital Markets | |
03.11.23 | Moderna Buy | Goldman Sachs Group Inc. |
Aktien in diesem Artikel
Moderna Inc | 41,17 | -2,60% |